<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849042</url>
  </required_header>
  <id_info>
    <org_study_id>ROMEO-AD 14394A</org_study_id>
    <nct_id>NCT01849042</nct_id>
  </id_info>
  <brief_title>Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease</brief_title>
  <acronym>ROMEO-AD</acronym>
  <official_title>A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacological efficacy on language capability and compliance
      with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients
      with probable Alzheimer's disease. Primary objective is to evaluate the efficacy of memantine
      on language capability in moderate to severe Alzheimer's disease patients who are taking
      stable donepezil treatment.Secondary objectives are to evaluate the efficacy of maintain on
      cognitive function and disease progression with K-MMSE, NPI, ROSA, and SIB-short form in
      probable AD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AQ-WAB(Western aphasia battery)</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ROSA (Relevant Outcome Scale for Alzheimer's Disease)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>SIB-short form</measure>
    <time_frame>six months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>donepezil maintain group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>add-on Ebixa oral pump group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ebixa</intervention_name>
    <description>add-on of Ebixa oral pump already receiving donepezil with stable dosage</description>
    <arm_group_label>add-on Ebixa oral pump group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
    <arm_group_label>donepezil maintain group</arm_group_label>
    <arm_group_label>add-on Ebixa oral pump group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  probable Alzheimer's disease in accordance with NINCDS-ADRDA criteria

          -  MMSE score equal to or less than 20

          -  Brain CT or MRI scan performed within the past 12 months

          -  living or having regular visit at least three times a week from caregiver

          -  able to visit outpatient clinic and to perform cognitive function test

          -  already taking stable dose of donepezil for 3 months prior to screening

          -  subject and caregiver who signed informed consent

        Exclusion Criteria:

          -  involved in another clinical trial within 4 weeks prior to screening

          -  severe or unstable disease: acute or severe asthma, unstable or severe cardiovascular
             disease, acute peptic ulcer,chronic renal failure

          -  bradycardia (pulse rate less than 50bpm), sick sinus syndrome

          -  any laboratory finding including cognitive impairments(vitamine B12 or folic acid,
             syphilis, thyroid disease)

          -  severe auditory or visual disturbance

          -  other degenerative disease or psychosis

          -  taken any drug used for the treatment of Alzheimer's disease or dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seol-Heui Han, PhD. MD</last_name>
    <phone>82-2-2030-7561</phone>
    <email>alzdoc@gw.kuh.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun Jeong Han, PhD. MD</last_name>
    <phone>82-10-4489-8742</phone>
    <email>neurohan@kd.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Konkuk university medical center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seol-Heui Han, PhD. MD</last_name>
      <phone>82-10-6309-5630</phone>
      <email>alzdoc@gw.kuh.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Seol-Heui Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

